Since MIS416 vaccination enhanced antigen-specific CTL accumulation in the tumor microenvironment and systemically while also promoting the accumulation of immunosuppressive myeloid cells, we reasoned that vaccination followed by non-selective myeloid depletion using anti-CD11b mAb to target both tumor-associated macrophages and MDSCs might prolong vaccine-induced anti-tumor immunity. Here, ITGAM is linked to neoplasm.